1997 年 30 巻 2 号 p. 203-210
Cell kinetics of bone and soft tissue tumors was assessed using 12 malignant tumors (3 cases of malignant fibrous histiocytoma, 3 cases of osteosarcoma, 2 cases of liposarcoma, 1 case each of synovial sarcoma, malignant lymphoma, malignant schwannoma and dedifferentiated chondrosarcoma) that were collected during operation in our department and subcultured by transplanting in nude mice. After intraperitoneal injection of iododeoxyuridine (IUdR) and bromodeox-yuridine (BrdU), tumor-bearing mice were sacrificed. Histological sections of the tumors were double-stained with mono-clonal antibodies for these compounds and examined. BrdU-labeling index for the tumors was 5-37%, duration of S phase was 13-34 hr, and potential doubling time was 54-375 hr. To our knowledge, no studies in which these values were measured in malignant tumors of bone and soft tissues have been reported. These values are fundamentally similar to those of carcinomas and leukemias reported before in another fields. In the present study the potential doubling time tended to be short in tumors that were clinicopathologically graded as highly malignant and exhibited poor prognosis. Also, the potential doubling time correlated closely with the tumor volume doubling time obtained by actual measuring in the diameter of tumors. These findings indicated that the potential doubling time of bone and soft tissue tumors may be a useful prognostic indicator beyond the different histologic diagnoses. In addition, they suggested possible and practical utilization of the potential doubling time in anti-cancer drug-sensitivity tests of tumors and application to planning therapeutic strategies against musculoskeletal sarcomas.
